Scholar Rock Holding (SRRK) Profit After Tax (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Profit After Tax came in at -$105.5 million in Q1 2026, down 41.2% year-on-year from -$179.4 million in Q1 2025, and down 458639.13% quarter-over-quarter from -$23000.0 in Q4 2025.
Scholar Rock Holding (SRRK) Profit After Tax (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Profit After Tax history runs 10 years deep, the most recent figure standing at -$105.5 million for Q1 2026.
- On a quarterly basis, Profit After Tax fell 41.2% year-over-year to -$105.5 million in Q1 2026; TTM through Mar 2026 was -$317.7 million, a 60.73% decrease from a year earlier, with the FY2025 full-year figure at -$66000.0, down 197.06% from the prior year.
- Profit After Tax eased to -$105.5 million in Q1 2026 per SRRK's latest filing, from -$23000.0 in the prior quarter.
- Across five years, Profit After Tax topped out at $32000.0 in Q4 2024 and bottomed at -$110.0 million in Q2 2025.
- The 5-year median for Profit After Tax is -$44.0 million (2022), against an average of -$51.4 million.
- Across the five-year window, Profit After Tax plunged 395.33% in 2023 and jumped 100.07% in 2024, its largest moves.
- Year by year, Profit After Tax stood at -$39.2 million in 2022, then fell by 19.86% to -$47.0 million in 2023, then soared by 100.07% to $32000.0 in 2024, then tumbled by 171.88% to -$23000.0 in 2025, then sank by 458639.13% to -$105.5 million in 2026.
- Per Business Quant, the three latest SRRK Profit After Tax figures stand at -$105.5 million (Q1 2026), -$23000.0 (Q4 2025), and -$102.2 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Scholar Rock Holding | 6.10 Bn | 6.10 Bn | - | -105.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -105.51 Mn |
| Dec 31, 2025 | -23,000.00 |
| Sep 30, 2025 | -102.16 Mn |
| Jun 30, 2025 | -110.03 Mn |
| Mar 31, 2025 | -74.72 Mn |
| Dec 31, 2024 | 32,000.00 |
| Sep 30, 2024 | -64.48 Mn |
| Jun 30, 2024 | -58.51 Mn |
| Mar 31, 2024 | -56.85 Mn |
| Dec 31, 2023 | -46.99 Mn |
| Sep 30, 2023 | -42.36 Mn |
| Jun 30, 2023 | -37.93 Mn |
| Mar 31, 2023 | -39.38 Mn |
| Dec 31, 2022 | -39.20 Mn |
| Sep 30, 2022 | -43.30 Mn |
| Jun 30, 2022 | -44.00 Mn |
| Mar 31, 2022 | -7.95 Mn |
| Dec 31, 2021 | 95.85 Mn |
| Sep 30, 2021 | -37.51 Mn |
| Jun 30, 2021 | -30.71 Mn |